Roger Tell
Chief Medical Officer
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Roger Tell is the Chief Medical Officer at Isofol in Sweden. His research areas focus primarily on metastatic colorectal cancer, encompassing gene expression, combination chemotherapy, and immunotherapy. He has authored several significant articles, including studies on arfolitixorin and its applications in oncological treatments. His work aims to enhance treatment efficacy and patient outcomes in complex cancer cases.
Articles (12)
TPS254 Background: Arfolitixorin ([6R]-5,10-methylene-tetrahydrofolate) is a direct-acting folate in development that may enhance treatment outcomes in patients with mCRC by bypassing the multi-step metabolic activation required by leucovorin (LV), the most commonly used folate agent. In a Phase 3 study with bevacizumab (NCT03750786), ARFOX (arfolitixorin, 5FU, oxaliplatin) demonstrated efficacy comparable to standard mFOLFOX6 (LV, 5FU, oxaliplatin), but did not achieve the primary endpoint of superiority, potentially due to a suboptimal arfolitixorin dose for a cellular response. Recent preclinical studies have indeed shown a clear dose–response relationship, with increased arfolitixorin activity at higher doses. This new Phase 1b/2 study (ClinicalTrials.gov: NCT06922383; EU Clinical Trials: 2024-516802-43-00) is therefore investigating the safety and maximum tolerated dose (MTD) of arfolitixorin at doses ≥120 mg/m² within the ARFOX and bevacizumab regimen, with the aim of later assessing efficacy. Methods: The study comprises a single-centre Phase 1b dose-finding stage (N=~20; ~1–3 patients/dose level, maximum 6 patients/dose) and a randomised Phase 2 dose-optimisation stage at ~3 sites in Germany (N=~40). Adult patients with RAS mutant mCRC eligible for first-line 5-FU, oxaliplatin, and bevacizumab undergo baseline assessments within 28 days prior to initiating treatment. Imaging (CT or MRI) is performed after 6 and 12 weeks, and every 12 weeks thereafter as long as on study treatment. All eligible patients receive ARFOX and bevacizumab every 14 days (+7 days) until disease progression or clinical deterioration per investigator’s judgment. In Phase 1b, arfolitixorin dosing begins at 120 mg/m², escalating to 200, 300, 400, and up to 500 mg/m², administered until the MTD is identified by the Safety Review Committee, with dose adjustments made at their discretion. In Phase 2, patients will be randomised (1:1) to one of two arfolitixorin dose levels: the MTD identified in Phase 1b and a dose one level below the MTD. Key endpoints of the Phase 1b/2 study include safety, tolerability, efficacy outcomes (objective response rate, progression-free and overall survival), and pharmacokinetics. Patient enrolment is ongoing as of August 2025. This abstract was previously presented by Dr. Sebastian Stintzing et al. at the ESMO Congress 2025 (Final Publication Number: 908eTiP) and is reused here with permission. Clinical trial information: EU Clinical trial number: 2024-516802-43-00 .
Year:
2026
Background 5‐Fluorouracil (5‐ FU ) and the Folate Leucovorin ( LV ) form the chemotherapy backbone for metastatic colorectal cancer ( mCRC ). Tumoral expression of specific folate‐associated genes is associated with the risk of recurrence in stage III CRC following adjuvant 5‐ FU / LV ( FLV )‐based combination chemotherapy according to the Nordic bolus regimen. The aim was to evaluate whether expression of folate‐associated genes in Pre‐therapeutic tumor samples is associated with outcomes of patients with mCRC undergoing palliative FLV ‐based combination chemotherapy. Patients and Methods Patients treated with FLV ( n = 113), FLV + oxaliplatin (FLOX, n = 102), or FLV + irinotecan (FLIRI, n = 75) were included. ABCC3 , RFC‐1, PCFT , MFT , MTHFD2 , and TYMS expression was determined by qPCR and related to tumor response and 3‐year progression‐free survival (PFS). Analyses were conducted on the entire cohort and on subgroups (group 1: stage I–III; group 2: stage IV, at primary surgery). Multivariate Cox proportional hazard models were applied to assess associations between covariates and PFS. Results Low TYMS and high MFT expression in group 1, and high ABCC3 expression in group 2 correlated with better PFS (HR 1.37 (1.04–1.82), HR 0.49 (0.30–0.80), and HR 0.74 (0.60–0.93)), respectively. In addition, high MFT expression was associated with better PFS of patients treated with FLIRI (HR 0.47 (0.27–0.81), p = 0.007) whereas high expression of ABCC3 was associated with better PFS of patients treated with FLOX (HR 0.46 (0.23–0.92), p = 0.029). Conclusion While pretherapeutic tumoral expression of specific folate‐associated genes may not serve as a universal predictive marker for FLV‐based treatment, it might predict response and outcomes in patients receiving FLOX or FLIRI. Evaluating the impact of gene expression in primary tumors should consider subgrouping of patients by disease stage at diagnosis as well as the applied chemotherapy regimen. Prospective clinical studies on patients with mCRC are warranted to validate these findings.
Year:
2025
Year:
2025
Year:
2025
Purpose: Suboptimal treatment outcomes with 5-fluorouracil (5-FU)/folate, the standard of care for metastatic colorectal cancer (mCRC), have generated interest in optimizing the folate. Arfolitixorin ([6R]-5,10-methylene-tetrahydrofolate) is an immediately active folate and may improve outcomes over the existing standard of care (leucovorin). Experimental Design: AGENT was a randomized, phase III study (NCT03750786). Patients with mCRC were randomized to arfolitixorin (120 mg/m2 given as two intravenous bolus doses of 60 mg/m2) or leucovorin (400 mg/m2 given as a single intravenous infusion) plus 5-FU, oxaliplatin, and bevacizumab. Assessments were performed every 8 weeks. The primary endpoint was the superiority of arfolitixorin for overall response rate (ORR). Results: Between February 2019 and April 2021, 490 patients were randomized (245 to each arm). After a median follow-up of 266 days, the primary endpoint of superiority for ORR was not achieved (48.2% for arfolitixorin vs. 49.4% for leucovorin, Psuperiority = 0.57). Outcomes were not achieved for median progression-free survival (PFS; 12.8 and 11.6 months, P = 0.38), median duration of response (12.2 and 12.9 months, P = 0.40), and median overall survival (23.8 and 28.0 months, P = 0.78). The proportion of patients with an adverse event of grade ≥3 severity was similar between arms (68.7% and 67.2%, respectively), as was quality of life. BRAF mutations and MTHFD2 expression were both associated with a lower PFS with arfolitixorin. Conclusions: The study failed to demonstrate clinical benefit of arfolitixorin (120 mg/m2) over leucovorin. However, it provides some useful insights from the first-line treatment setting, including the effect of gene expression on outcomes. Significance: This phase III study compared arfolitixorin, a direct-acting folate, with leucovorin in FOLFOX plus bevacizumab in mCRC. Arfolitixorin (120 mg/m2) did not improve the ORR, potentially indicating a suboptimal dose.
Year:
2024
Gene expression across responses categories and treatments. Dots represent outliers. CR, complete response; NE, non-evaluable; PR, partial response; PD, progressive disease; SD, stable disease.
Year:
2024
Gene expression across responses categories and treatments. Dots represent outliers. CR, complete response; NE, non-evaluable; PR, partial response; PD, progressive disease; SD, stable disease.
Year:
2024
Purpose: Suboptimal treatment outcomes with 5-fluorouracil (5-FU)/folate, the standard of care for metastatic colorectal cancer (mCRC), have generated interest in optimizing the folate. Arfolitixorin ([6R]-5,10-methylene-tetrahydrofolate) is an immediately active folate and may improve outcomes over the existing standard of care (leucovorin). Experimental Design: AGENT was a randomized, phase III study (NCT03750786). Patients with mCRC were randomized to arfolitixorin (120 mg/m 2 given as two intravenous bolus doses of 60 mg/m 2 ) or leucovorin (400 mg/m 2 given as a single intravenous infusion) plus 5-FU, oxaliplatin, and bevacizumab. Assessments were performed every 8 weeks. The primary endpoint was the superiority of arfolitixorin for overall response rate (ORR). Results: Between February 2019 and April 2021, 490 patients were randomized (245 to each arm). After a median follow-up of 266 days, the primary endpoint of superiority for ORR was not achieved (48.2% for arfolitixorin vs. 49.4% for leucovorin, P superiority = 0.57). Outcomes were not achieved for median progression-free survival (PFS; 12.8 and 11.6 months, P = 0.38), median duration of response (12.2 and 12.9 months, P = 0.40), and median overall survival (23.8 and 28.0 months, P = 0.78). The proportion of patients with an adverse event of grade ≥3 severity was similar between arms (68.7% and 67.2%, respectively), as was quality of life. BRAF mutations and MTHFD2 expression were both associated with a lower PFS with arfolitixorin. Conclusions: The study failed to demonstrate clinical benefit of arfolitixorin (120 mg/m 2 ) over leucovorin. However, it provides some useful insights from the first-line treatment setting, including the effect of gene expression on outcomes. Significance: This phase III study compared arfolitixorin, a direct-acting folate, with leucovorin in FOLFOX plus bevacizumab in mCRC. Arfolitixorin (120 mg/m 2 ) did not improve the ORR, potentially indicating a suboptimal dose.
Year:
2024
Purpose: Suboptimal treatment outcomes with 5-fluorouracil (5-FU)/folate, the standard of care for metastatic colorectal cancer (mCRC), have generated interest in optimizing the folate. Arfolitixorin ([6R]-5,10-methylene-tetrahydrofolate) is an immediately active folate and may improve outcomes over the existing standard of care (leucovorin). Experimental Design: AGENT was a randomized, phase III study (NCT03750786). Patients with mCRC were randomized to arfolitixorin (120 mg/m 2 given as two intravenous bolus doses of 60 mg/m 2 ) or leucovorin (400 mg/m 2 given as a single intravenous infusion) plus 5-FU, oxaliplatin, and bevacizumab. Assessments were performed every 8 weeks. The primary endpoint was the superiority of arfolitixorin for overall response rate (ORR). Results: Between February 2019 and April 2021, 490 patients were randomized (245 to each arm). After a median follow-up of 266 days, the primary endpoint of superiority for ORR was not achieved (48.2% for arfolitixorin vs. 49.4% for leucovorin, P superiority = 0.57). Outcomes were not achieved for median progression-free survival (PFS; 12.8 and 11.6 months, P = 0.38), median duration of response (12.2 and 12.9 months, P = 0.40), and median overall survival (23.8 and 28.0 months, P = 0.78). The proportion of patients with an adverse event of grade ≥3 severity was similar between arms (68.7% and 67.2%, respectively), as was quality of life. BRAF mutations and MTHFD2 expression were both associated with a lower PFS with arfolitixorin. Conclusions: The study failed to demonstrate clinical benefit of arfolitixorin (120 mg/m 2 ) over leucovorin. However, it provides some useful insights from the first-line treatment setting, including the effect of gene expression on outcomes. Significance: This phase III study compared arfolitixorin, a direct-acting folate, with leucovorin in FOLFOX plus bevacizumab in mCRC. Arfolitixorin (120 mg/m 2 ) did not improve the ORR, potentially indicating a suboptimal dose.
Year:
2024
Year:
2022
Year:
2020
Year:
2020
Collaborators (5)
Heinz-Josef Lenz
University of Southern California
Gerald W. Prager
Medical University of Vienna
Sebastian Stintzing
Professor
Charité - Universitätsmedizin Berlin
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Christos Papadimitriou
-
Make your next move.
Prepare your application
Review drafts before you send them.